Media Contact: Dave Johnson
FOR IMMEDIATE RELEASE
DSI and Nova sign supply agreement to manufacture telemetry implant for diabetes research.
St. Paul, MN, March 3, 2013 - Data Sciences International (DSI) announced today that Nova Biomedical (Nova) and DSI have signed a supply agreement for the development and manufacture of a fully implanted telemetry device for the continuous measurement of blood glucose in animal research applications.
The Centers for Disease Control and Prevention (CDC) estimates that diabetes affects 26 million people in the U.S. alone, or 8.3% of the population1. Diabetes is a major cause of heart disease, stroke, kidney failure, lower-limb amputations, and blindness. The National Institutes of Health (NIH) is providing an estimated 1 billion dollars in funding for diabetes research in 20142. In addition, with nearly every major pharmaceutical company engaged in the development of new treatments for diabetes and metabolic disease, demand for better research instrumentation has also increased.
“There is a lack of preclinical continuous glucose measurement tools; DSI’s industry leadership in chronic in vivo monitoring combined with Nova’s leadership in sensor technology promises a big leap forward in how diabetes research will be conducted in the future,” said Bert Harman, CEO at DSI. “We are excited about the development of a glucose telemetry implant and we believe that this will drive many new market opportunities at DSI.”
The sensor leverages Nova’s vast experience in blood chemistry sensing in clinical applications. “We are pleased with the DSI partnership and the opportunity to offer preclinical researchers state-of-the-art blood glucose sensing technology,” stated Chief Technology Officer Dr. CC Young of Nova.
DSI is a pioneering biomedical company focused on preclinical systems for physiology and pharmacology research. The recognized global leader in physiologic monitoring, DSI offers telemetry, instrumentation, software and services that help advance science. DSI serves many industries including: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, the Medical Device Industry, Government, and Biotechnology companies. Solutions are tailored specifically to meet the unique research needs of their customers.
Visit http://www.datasci.com for more about the company.
ABOUT NOVA BIOMEDICAL
Nova Biomedical develops, manufactures and sells advanced technology blood testing analyzers based on electrochemical and optical measuring techniques.
Visit http://www.novabiomedical.com for more about the company.
- CDC website. Diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/factsheets.htm
- NIH Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). April 10, 2013 http://report.nih.gov/categorical_spending.aspx